As of 2026-09-23, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -37.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 16,236.34 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -434.63 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.8x - 15.9x | 15.0x |
| Forward P/E multiples | 13.9x - 16.5x | 15.0x |
| Fair Price | (44.60) - (49.04) | (46.90) |
| Upside | -164.4% - -170.8% | -167.7% |
| Date | EV/EBITDA |
| 2026-09-21 | -36.11 |
| 2026-09-18 | -36.18 |
| 2026-09-17 | -36.49 |
| 2026-09-16 | -36.94 |
| 2026-09-15 | -36.98 |
| 2026-09-14 | -38.78 |
| 2026-09-11 | -38.80 |
| 2026-09-10 | -38.83 |
| 2026-09-09 | -40.44 |
| 2026-09-08 | -39.85 |
| 2026-09-04 | -39.88 |
| 2026-09-03 | -40.14 |
| 2026-09-02 | -40.63 |
| 2026-09-01 | -40.66 |
| 2026-08-31 | -40.67 |
| 2026-08-28 | -40.68 |
| 2026-08-27 | -41.61 |
| 2026-08-26 | -41.93 |
| 2026-08-25 | -42.39 |
| 2026-08-24 | -42.69 |
| 2026-08-21 | -42.89 |
| 2026-08-20 | -43.53 |
| 2026-08-19 | -43.99 |
| 2026-08-18 | -43.55 |
| 2026-08-17 | -42.16 |
| 2026-08-14 | -42.15 |
| 2026-08-13 | -42.76 |
| 2026-08-12 | -43.94 |
| 2026-08-11 | -43.88 |
| 2026-08-10 | -44.31 |
| 2026-08-07 | -44.23 |
| 2026-08-06 | -43.47 |
| 2026-08-05 | -43.11 |
| 2026-08-04 | -43.14 |
| 2026-08-03 | -42.19 |
| 2026-07-31 | -42.25 |
| 2026-07-30 | -43.17 |
| 2026-07-29 | -43.80 |
| 2026-07-28 | -44.71 |
| 2026-07-27 | -44.07 |
| 2026-07-24 | -44.02 |
| 2026-07-23 | -43.53 |
| 2026-07-22 | -43.41 |
| 2026-07-21 | -43.31 |
| 2026-07-20 | -42.55 |
| 2026-07-17 | -42.83 |
| 2026-07-16 | -42.34 |
| 2026-07-15 | -43.41 |
| 2026-07-14 | -44.05 |
| 2026-07-13 | -43.60 |